Fusion Antibodies PLC (FAB:AIM) delivers an investor-focused update highlighting its strategic transformation towards fully integrated, next-generation antibody discovery services, underpinned by the forthcoming launch of its first-in-class Optimal platform and growing commercial traction across humanization, engineering, and AI-enabled antibody design. The company reiterates its core position as a CRO specialising in therapeutic antibody discovery and development, addressing a global market forecast to grow from $253bn in 2024 to nearly $500bn by 2029, with strong demand for faster, higher-quality candidate generation. Management emphasises its shift from being known primarily for industry-leading humanization capabilities to providing end-to-end discovery-to-cell-line offerings through Optimal, Optiphage, and AIM Lab, enabling client retention from target nomination through clinic-ready cell lines. Pre-launch validation with the National Cancer Institute has confirmed Optimal’s best-in-class performance, delivering single-digit nanomolar binders across proteins and peptides, supporting strong early expressions of interest. H1 revenue of £0.84m represents an 11% improvement versus H2 FY25, with gross margin improving to 30% (from 13.9% in H2), EBITDA loss reduced by 47.4%, and disciplined cash management holding cash at £252k. R&D investment increased to £350k, supported by FMI and DR5 grant inflows, while post-period highlights include a contract win with a European global pharma group and continued strengthening of the company’s reputation as a leading humanization provider. Management reiterates confidence in the commercial opportunity ahead of Optimal’s December launch, supported by operational momentum, strengthened margins, and increasing industry engagement.